The healthcare group Fresenius has nearly completed the work begun two years ago to expand company headquarters in Bad Homburg. Two new office buildings; “EK3” at Else-Kröner Street and “D15A” located at Daimler Street have been in operation since April. Now the redesigned exterior grounds fronting Else-Kröner Street are completed. These grounds link the additions with existing buildings to create the new “Fresenius Campus.”

To mark the occasion, the company leadership yesterday invited employees who work on the premise to a “Campus Fest.” Together with Bad Homburg Lord Mayor Alexander Hetjes and Fresenius Chief Executive Officer Stephan Sturm, they celebrated this new milestone in Fresenius company history.

In opening remarks, Stephan Sturm emphasized the ongoing growth at Fresenius, both worldwide and in the spa city. “Only 10 years ago we had about 2,000 employees in Bad Homburg. Now we have twice as many. All the signs point to continued growth in the future – because demand for our products and services is growing worldwide, and because our employees are doing everything they can to meet this demand.”

“The company’s headquarters also symbolizes the impressive growth of Fresenius, which continues to make its mark on Bad Homburg as a business location,” said Hetjes. “The energy efficiency is exemplary, and thanks to the headquarters’ campus character and modern design the company can offer employees a very attractive working environment in our city.”

Construction on EK3 began in September, 2017. The five-story building accommodates 600 modern office workspaces, conference rooms, an additional employee cafeteria and an underground parking garage. Work on D15A began in May, 2018. This building expands on the existing Research & Development Center of Fresenius Medical Care, to which it is connected by a footbridge. It offers 150 office workspaces spread over six floors.

Altogether Fresenius invested 70 million euros in the headquarters expansion. The company currently employs about 4,000 people in Bad Homburg and another 300 in neighboring Oberursel.

Construction on another office building to be rented by Fresenius, Uniqus 2 at Horex Street, is expected to be finished by the end of this year. The building will accommodate 250 workspaces.

Fulvestrant Injection is now available in the United States in the company’s ready-to-administer prefilled syringes and is the latest addition to Fresenius Kabi’s broad oncology portfolio. The product is the only room temperature stable Fulvestrant Injection currently available in the U.S.

Fresenius Helios has developed a new system for measuring patient safety, and is introducing it in all 86 Helios hospitals across Germany. The new system will complement the company’s existing quality management system and combine internationally established patient safety indicators with various indicators that Helios has developed through clinical practice. These include measurements on such indicators as false diagnoses, medication errors and patient falls. When Helios begins reporting the results next year, it will be the first German hospital operator to provide patient safety data that can be compared internationally.

Fresenius Helios has developed a new system for measuring patient safety, and is introducing it in all 86 Helios hospitals across Germany. The new system will complement the company’s existing quality management system and combine internationally established patient safety indicators with various indicators that Helios has developed through clinical practice. These include measurements on such indicators as false diagnoses, medication errors and patient falls. When Helios begins reporting the results next year, it will be the first German hospital operator to provide patient safety data that can be compared internationally.